ABCR评分系统对经肝动脉化疗栓塞术治疗肝细胞癌预后的评估价值

杨俊; 印于; 倪才方; 朱晓黎; 李智; 张申; 黄鹏; 王万胜

doi:10.3969/j.issn.1001-5256.2020.09.014

ABCR评分系统对经肝动脉化疗栓塞术治疗肝细胞癌预后的评估价值

DOI: 10.3969/j.issn.1001-5256.2020.09.014

苏州大学附属第一医院介入科

基金项目:

苏州市科技计划项目(SYS2019036)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1245
- HTML全文浏览量: 25
- PDF下载量: 121
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Value of ABCR scoring system in assessing the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization

Department of Interventional Radiology, The First Affiliated Hospital of Soochow University

Research funding:

摘要

摘要:
目的评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略。方法选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者。为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗（至少2次,且不联合全身系统治疗）的229例患者为A组,并分为A1组（ABCR评分≤0,n=92）、A2组（ABCR评分:1～3分,n=78）和A3组（ABCR评分≥4,n=59）;为研究ABCR评分为1-3分患者首次TACE治疗后接受不同治疗方案的生存期,选取首次行TACE治疗的ABCR评分为1～3分的118例患者为B组,分为B1组（首次TACE后继续TACE,n=78）、B2组（TACE联合索拉非尼,n=21）和B3组（索拉非尼单药治疗,n=19）。分析以上各组患者的生存情况。计数资料组间比较采用Fisher精确检验,Kaplan-Meier法绘制生存曲线,log-rank检验比较各组生存期。结果 A1组中位生存期32.0个月（95%CI:27.7～36.3）; A2组中位生存期10.3个月（95%CI:8.4...
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- ABCR评分 /
- 索拉非尼
Abstract:
Objective To investigate the value of ABCR clinical scoring system in guiding repeated transcatheter arterial chemoembolization( TACE) therapy for patients with hepatocellular carcinoma( HCC) and the treatment strategies for patients with an ABCR score of 1-3.Methods The patients with HCC who underwent TACE in The First Affiliated Hospital of Soochow University from January 2008 to December 2017 were enrolled. In order to investigate the effect of repeated TACE in patients with different ABCR scores,229 patients who underwent repeated TACE consecutively( at least twice,without systemic therapy) were enrolled as group A,which was further divided into group A1 with 92 patients( an ABCR score of ≤0),group A2 with 78 patients( an ABCR score of 1-3),and group A3 with 59 patients( an ABCR score of ≥4). In order to investigate the survival time of patients with an ABCR score of 1-3 who received different regimens after first TACE therapy,118 patients with an ABCR score of 1-3 who received TACE for the first time were enrolled as group B,which was further divided into group B1 with 78 patients( treated with TACE after first TACE therapy),group B2 with 21 patients( treated with TACE combined with sorafenib),and group B3 with 19 patients( treated with sorafenib alone). The survival of the above groups of patients were analyzed. The Fisher's exact test was used for comparison of categorical data between groups,the Kaplan-Meier method was used to plot survival curves,and the log-rank test was used for comparison of survival time between groups. Results The median survival time was32. 0 months( 95% confidence interval [CI]: 27. 7-36. 3) in group A1,10. 3 months( 95% CI: 8. 4-12. 2) in group A2,and 4. 6 months( 95% CI: 3. 7-5. 5) in group A3. Group A1 had a better survival time than group A2( χ2= 106. 99,P < 0. 01),and group A2 had a better survival time than group A3( χ2= 49. 66,P < 0. 01). The median survival time was 10. 3 months( 95% CI: 8. 4-12. 2) in group B1,14. 8 months( 95% CI: 7. 8-21. 8) in group B2,and 6. 0 months( 95% CI: 4. 6-7. 4) in group B3,and group B2 had a better survival time than group B1( χ2= 6. 80,P < 0. 01) and group B3( χ2= 29. 89,P < 0. 01). Conclusion The ABCR score has a certain guiding significance for the treatment of HCC patients. Repeated TACE may be considered for patients with an ABCR score of ≤0,while patients with an ABCR score of ≥4 may not benefit from further TACE therapy,and TACE combined with sorafenib might bring maximum benefits to patients with an ABCR score of 1-3.
- carcinoma,hepatocellular /
- chemoembolization,therapeutic /
- ABCR score /
- sorafenib

HTML全文

参考文献(20)

[1] RAOUL JL,FORNER A,BOLONDI L,et al. Updated use of TACE for hepatocellular carcinoma treatment:How and when to use it based on clinical evidence[J]. Cancer Treat Rev,2019,72:28-36.

[2] LV WF,LIU KC,LU D,et al. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis[J]. Cancer Manag Res,2018,10:4719-4726.

[3] CHO YY,YU SJ,YOO JJ,et al. The model to estimate survival in ambulatory hepatocellular carcinoma patients aids in the decision for TACE retreatment[J]. J Clin Gastroenterol,2020,54(4):370-377.

[4] ADHOUTE X,PENARANDA G,NAUDE S,et al. Retreatment with TACE:The ABCR SCORE,an aid to the decision-making process[J]. J Hepatol,2015,62(4):855-862.

[5] PINATO DJ,HOWELL J,RAMASWAMI R,et al. Review article:Delivering precision oncology in intermediate-stage liver cancer[J]. Aliment Pharmacol Ther,2017,45(12):1514-1523.

[6] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.

[7] SIEGHART W,HUCKE F,PINTER M,et al. The ART of decision making:Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology,2013,57(6):2261-2273.

[8] KLOECKNER R,PITTON MB,DUEBER C,et al. Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma[J]. J Vasc Interv Radiol,2017,28(1):94-102.

[9] WANG XF,ZHU LY,LU BL,et al. Application of different scoring systems in evaluating prognosis after transarterial chemoembolization for primary livercancer[J]. J Clin Hepatol,2017,33(10):2016-2020．汪晓芳，朱丽影，卢宝玲，等．不同评分系统在原发性肝癌肝动脉化疗栓塞术预后判断中的应用[J]．临床肝胆病杂志，2017,33(10):2016-2020.

[10] CHEN CS,HU HT,XIAO JC,et al. The value of ABCR score in guiding the second time of TACE treatment for patients with hepatocellular carcinoma[J]. J Intervent Radiol,2016,25(10):918.(in Chinese)陈呈世，胡鸿涛，肖金成，等．ABCR评分对肝细胞癌患者再次行TACE治疗的指导作用[J]．介入放射学杂志，2016,25(10):918.

[11] CHANG QQ,PENG Y,WANG GJ,et al. Clinical research progress of small molecule tyrosine kinase inhibitors as antihepatocellular carcinoma agents[J]. Chin J Clin Pharmacol Ther,2019,24(8):948-956.(in Chinese)常青青，彭英，王广基，等．抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]．中国临床药理学与治疗学，2019,24(8):948-956.

[12] PRESSIANI T,BONI C,RIMASSA L,et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma:A prospective feasibility analysis[J]. Ann Oncol,2013,24(2):406-411.

[13] LEE S,KANG JH,KIM DY,et al. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization[J]. Hepatol Int,2017,11(3):292-299.

[14] VARGHESE J,KEDARISETTY C,VENKATARAMAN J,et al.Combination of TACE and sorafenib improves outcomes in BCLC stages B/C of hepatocellular carcinoma:A single centre experience[J]. Ann Hepatol,2017,16(2):247-254.

[15] WANG Q,XIA D,BAI W,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma:A multicentre observational study[J]. J Hepatol,2019,70(5):893-903.

[16] CHUNG GE,LEE JH,KIM HY,et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival[J]. Radiology,2011,258(2):627-634.

[17] KOK VC,CHEN YC,CHEN YY,et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma:A nationwide population-based cohort study[J]. Cancers(Basel),2019,11(7):985.

[18] WU FX,CHEN J,BAI T,et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma[J]. BMC Cancer,2017,17(1):645.

[19] REN B,WANG W,SHEN J,et al. Transarterial chemoembolization(TACE)combined with sorafenib versus TACE alone for unresectable hepatocellular carcinoma:A propensity score matching study[J]. J Cancer,2019,10(5):1189-1196.

[20] WU J,LI A,YANG J,et al. Efficacy and safety of TACE in combination with sorafenib for the treatment of TACE-refractory advanced hepatocellular carcinoma in Chinese patients:A retrospective study[J]. Onco Targets Ther,2017,10:2761-2768.

施引文献

资源附件(0)

访问统计